-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 27, GSK announced its 2022Q1 results, achieving revenue of 9.
The new crown neutralizing antibody Xevudy (Sotrovimab) brought in 1.
The sales revenue of Shingrix, a shingles vaccine, was 698 million pounds, an increase of more than 100% year-on-year, setting a new quarterly sales revenue record.
In addition to the above two extremely high-growth drugs, GSK has achieved high double-digit growth in the HIV, immune-inflammatory and respiratory diseases, and oncology business areas compared with the same period last year
After GSK returned to the oncology track, although the business revenue has also increased well, the overall volume is not large.
In the first quarter, GSK's key actions in drug research and development included:
FDA approves Cabenuva for virally suppressed adolescent HIV-infected patients and Triumeq dispersible tablets for pediatric HIV-infected patients;
The marketing application for the hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) daprodustat was submitted and accepted by the FDA for the treatment of anemia in patients with chronic kidney disease (CKD), with a PDUFA date of February 1, 2023
Benlysta is approved in China for the treatment of active lupus nephritis
The consumer health business also contributed to GSK's good growth in the first quarter, but GSK announced on February 22 that it would spin off the consumer health business in July 2022, and named the new company "health".
English link: https:// href="https://" target="_blank">https://
